pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Mounjaro
drug · protein
save

tirzepatide

pre_registrationupdated 3mo ago
by Eli Lilly and Co🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 6
  • drugZEPBOUND112 co-mentions · 40 sources
  • drugMOUNJARO112 co-mentions · 40 sources
  • tagApproval96 co-mentions · 24 sources
  • companyEli Lilly and Co48 co-mentions · 24 sources
  • tagRecall16 co-mentions · 16 sources
  • drugcyanocobalamin2 co-mentions · 2 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.

targets

Glucagon-like peptide 1 receptorGastric inhibitory polypeptide receptor

all catalysts(0)

nothing on the calendar yet

Trials studying tirzepatide

  • phase2A Study to Evaluate ALN-2232 in Participants With Obesityrecruitingn=156
  • phase3A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)recruitingn=4,500
  • phase4AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetesnot yet recruitingn=285
  • phase3A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)recruitingn=300
  • phase3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Bothactive not recruitingn=1,023
  • phase3Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweightrecruitingn=290
  • phase2A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidityactive not recruitingn=285
  • phase3Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Studyrecruitingn=350
more trials →

News(10)

  • Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
    Medicare’s new weight loss drug program “risks creating barriers at precisely the moment when confidence in broader GLP‑1 coverage is most needed,” writes Jeffrey Millstein.
    stat · 1d ago
  • Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
    A legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicin…
    biospace · 7d ago
  • Lilly climbs, Novo falls as obesity drug battle intensifies
    A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.
    biopharma_dive · 7d ago
  • Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
    Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the e…
    biospace · 7d ago
  • Novo CEO sees innovation as a matter of survival amid pipeline setbacks
    Novo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its…
    biospace · 7d ago
  • Lilly once again beats expectations as tirzepatide accounts for 64% of revenue
    Eli Lilly posted $23 billion in second-quarter revenues, coming in about $3 billion above analysts' estimates. Lilly also once again raised its full-year revenue guidance to between $85 billion and…
    endpoints · 7d ago
  • ‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
    Novo Nordisk CFO Karsten Munk Knudsen spoke to Fierce the morning the company unveiled its second-quarter earnings, reflecting on Novo’s “roller coaster” financial journey, the pressure of navigati…
    fiercebiotech · 7d ago
  • Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
    Novo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is…
    fiercebiotech · 7d ago
  • Lilly and Resilience invest $750M in diabetes and obesity drug device supply
    The investment will expand Resilience’s U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.
    biospace · 12d ago
  • Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
    Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.
    fiercebiotech · 12d ago
view all news mentions →
brand
Mounjaro
trade names
Mounjaro, Mounjaro (autoinjector), Zepbound, Zepbound (autoinjector)
generic
tirzepatide
MOA
Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist
indication
Cardiovascular Risk Factors
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?